nach oben

Medical Oncology

Erschienen in:

01.05.2015 | Original Paper

CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells

verfasst von: Asim Pervaiz, Shariq Ansari, Martin R. Berger, Hassan Adwan

Erschienen in: Medical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Alterations in the expression of C–C chemokine receptor type 5 (CCR5 or CD195) have been correlated with disease progression in different cancers. Recently, a few investigations have reported the blockage of this receptor by an antagonist (maraviroc) and its antineoplastic effects on tumor cell growth. However, little is known about the mechanistic reasons behind these antineoplastic effects of CCR5 blockage by maraviroc. In this study, we blocked the CCR5 receptor by maraviroc in SW480 and SW620 colorectal cancer cells to study the resulting changes in biological properties and related pathways. This blockage induced significantly reduced proliferation and a profound arrest in G1 phase of the cell cycle. Concomitantly, maraviroc caused significant signs of apoptosis at morphological level. Significant modulation of multiple apoptosis-relevant genes was also noticed at mRNA levels. In addition, we found remarkable increases in cleaved caspases at protein level. These modulations led us to propose a signaling pathway for the observed apoptotic effects. In conclusion, blocking the CCR5 by maraviroc induces significant cytotoxic and apoptotic effects in colorectal cancer cells. Thus, maraviroc can be considered a model compound, which may foster the development of further CCR5 antagonists to be used for the treatment of colorectal cancer.

Nur mit Berechtigung zugänglich

Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002;42:469–99. doi:10.1146/annurev.pharmtox.42.091901.115838.CrossRefPubMed

Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–7.CrossRefPubMed

Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today. 1999;20(6):254–7.CrossRefPubMed

Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–42. doi:10.1146/annurev.immunol.18.1.217.CrossRefPubMed

Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007;25:787–820. doi:10.1146/annurev.immunol.24.021605.090529.CrossRefPubMed

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0.CrossRefPubMed

Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404(6776):407–11. doi:10.1038/35006097.CrossRefPubMed

Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50. doi:10.1038/nrc1388.CrossRefPubMed

Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp Cell Res. 2011;317(5):575–89. doi:10.1016/j.yexcr.2011.01.005.CrossRefPubMedCentralPubMed

10.

Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21(1):27–39. doi:10.1016/j.cytogfr.2009.11.007.CrossRefPubMed

11.

Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16(3):133–44. doi:10.1016/j.molmed.2010.01.003.CrossRefPubMedCentralPubMed

12.

Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256(2):137–65. doi:10.1016/j.canlet.2007.05.013.CrossRefPubMedCentralPubMed

13.

Richmond A. Chemokine modulation of the tumor microenvironment. Pigment Cell Melanoma Res. 2010;23(3):312–3. doi:10.1111/j.1755-148X.2010.00714.x.CrossRefPubMedCentralPubMed

14.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

15.

Garborg K, Holme O, Loberg M, Kalager M, Adami HO, Bretthauer M. Current status of screening for colorectal cancer. Ann Oncol. 2013;24(8):1963–72. doi:10.1093/annonc/mdt157.CrossRefPubMed

16.

Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35(11):3362–7. doi:10.1021/bi952950g.CrossRefPubMed

17.

Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. 1996;271(29):17161–6.CrossRefPubMed

18.

Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16(11):1201–10. doi:10.1016/j.cellsig.2004.04.007.CrossRefPubMed

19.

New DC, Wong YH. CC chemokine receptor-coupled signalling pathways. Acta Biochimica et Biophysica Sinica. 2003;35(9):779–88.PubMed

20.

Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Muller M, et al. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int J Colorectal Dis. 2010;25(4):417–24. doi:10.1007/s00384-009-0868-y.CrossRefPubMed

21.

Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, et al. Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol. 2009;460:105–21. doi:10.1016/S0076-6879(09)05205-7.CrossRefPubMed

22.

Schimanski CC, Moehler M, Gockel I, Zimmermann T, Lang H, Galle PR, et al. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. J Cancer Res Clin Oncol. 2011;137(7):1139–45. doi:10.1007/s00432-011-0980-6.CrossRefPubMed

23.

Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 2014;352(1):36–53. doi:10.1016/j.canlet.2013.10.006.CrossRefPubMed

24.

de Oliveira CE, Oda JM, Losi Guembarovski R, de Oliveira KB, Ariza CB, Neto JS, et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers. 2014;2014:126954. doi:10.1155/2014/126954.CrossRefPubMedCentralPubMed

25.

Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012;72(5):1092–102. doi:10.1158/0008-5472.CAN-11-2493.CrossRefPubMed

26.

Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4(2):141–54. doi:10.1007/s12307-010-0052-5.CrossRefPubMedCentralPubMed

27.

Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS ONE. 2011;6(12):e28842. doi:10.1371/journal.pone.0028842.CrossRefPubMedCentralPubMed

28.

Ward ST, Li KK, Hepburn E, Weston CJ, Curbishley SM, Reynolds GM, et al. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer. 2015;112(2):319–28. doi:10.1038/bjc.2014.572.CrossRefPubMed

29.

Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm. 2009;66(8):715–26. doi:10.2146/ajhp080206.CrossRefPubMed

30.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.CrossRefPubMed

31.

Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72(15):3839–50. doi:10.1158/0008-5472.CAN-11-3917.CrossRefPubMed

32.

Ochoa-Callejero L, Perez-Martinez L, Rubio-Mediavilla S, Oteo JA, Martinez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE. 2013;8(1):e53992. doi:10.1371/journal.pone.0053992.CrossRefPubMedCentralPubMed

33.

Mencarelli A, Graziosi L, Renga B, Cipriani S, D’Amore C, Francisci D, et al. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013;6(6):784–93.CrossRefPubMedCentralPubMed

34.

Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol. 2008;65(Suppl 1):60–7. doi:10.1111/j.1365-2125.2008.03137.x.CrossRefPubMedCentralPubMed

35.

Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A, et al. Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev. 1999;13(22):3027–33.CrossRefPubMedCentralPubMed

36.

Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18(22):2699–711. doi:10.1101/gad.1256504.CrossRefPubMed

37.

Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO, et al. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol. 1999;19(1):612–22.PubMed

38.

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi:10.1080/01926230701320337.CrossRefPubMedCentralPubMed

39.

Lee SH, Meng XW, Flatten KS, Loegering DA, Kaufmann SH. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ. 2013;20(1):64–76. doi:10.1038/cdd.2012.93.CrossRefPubMedCentralPubMed

40.

Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, et al. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ. 2006;13(10):1619–30. doi:10.1038/sj.cdd.4402015.CrossRefPubMed

41.

Rautureau GJ, Day CL, Hinds MG. Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J Mol Sci. 2010;11(4):1808–24. doi:10.3390/ijms11041808.CrossRefPubMedCentralPubMed

42.

Xu G, Shi Y. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res. 2007;17(9):759–71. doi:10.1038/cr.2007.52.CrossRefPubMed

43.

Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7(4):313–9.CrossRefPubMed

44.

Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol. 2004;14(4):184–93. doi:10.1016/j.tcb.2004.03.002.CrossRefPubMed

45.

Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis. 2012;3:e338. doi:10.1038/cddis.2012.86.CrossRefPubMedCentralPubMed

Titel: CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells
verfasst von: Asim Pervaiz
Shariq Ansari
Martin R. Berger
Hassan Adwan
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-015-0607-x

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts

Chemoradiation therapy reduces aldehyde dehydrogenase 1 expression in cervical cancer but does not improve patient survival

Endothelial cell protein C receptor promotes MGC803 gastric cancer cells proliferation and migration by activating ERK1/2

Stromal interaction molecule 1 (STIM1) silencing inhibits tumor growth and promotes cell cycle arrest and apoptosis in hypopharyngeal carcinoma

Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study

Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie